Plant-based medicinal compounds or nutritional supplements in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. The plant-based composition/carrier combinations can create administration benefits.

The teachings provided herein generally relate to enhanced antivirulents that inactivate antibiotic-resistant bacteria as opposed to relying on an antimicrobial killing of the bacteria, and the antivirulents are safe for oral administration. As such, the systems taught herein are valuable methods that provide an alternate pathway for treating a subject having an antibiotic-resistant bacterial infection.

This invention is directed to the use of a combination of antioxidants which are delivered to the gut microbiome. The antioxidants are riboflavin, beta-carotene, Vitamin C and Vitamin E. We have found that they deliver a degree of improvement to gut health comparable to known prebiotics, such as soluble fibers.

This invention is directed to the use of a combination of antioxidants which are delivered to the gut microbiome. The antioxidants are riboflavin, beta-carotene, Vitamin C and Vitamin E. We have found that they deliver a degree of improvement to gut health comparable to known prebiotics, such as soluble fibers.

A galactomannan degradation product wherein a molecular weight distribution thereof satisfies the following requirements: a molecular weight of 12,000 or more is from 1 to 32%; a molecular weight of from 300 to 3,000 is from 25 to 60%; and a maximum of peak intensity in the molecular weight patterns of high-performance liquid chromatography exists within the range of a molecular weight of from 4,000 to 14,000. The galactomannan degradation product of the present invention can be used in various foodstuff, cosmetics, and the like.

The present disclosure relates generally to methods of treating (i) a tumor (e.g., a solid tumor, an advanced solid tumor, a cancer), (ii) tumor-related weight loss, or (iii) tumor-related cachexia in a human patient, the method comprising administering to the human patient an anti-GDNF family receptor alpha-like (GFRAL) antibody, wherein the antibody inhibits GFRAL binding to Ret proto-oncogene (RET). The present disclosure also relates generally to methods of treating pancreatic cancer (e.g., an advanced pancreatic cancer, a metastatic pancreatic cancer, a pancreatic adenocarcinoma, a metastatic pancreatic adenocarcinoma, an MSI-H pancreatic cancer, a pancreatic ductal adenocarcinoma, a metastatic pancreatic ductal adenocarcinoma) in a human patient, comprising administering to the human patient (i) an anti-GFRAL antibody, wherein the antibody inhibits GFRAL binding to RET; (ii) paclitaxel; and (iii) gemcitabine.

The present disclosure relates generally to methods of treating (i) a tumor (e.g., a solid tumor, an advanced solid tumor, a cancer), (ii) tumor-related weight loss, or (iii) tumor-related cachexia in a human patient, the method comprising administering to the human patient an anti-GDNF family receptor alpha-like (GFRAL) antibody, wherein the antibody inhibits GFRAL binding to Ret proto-oncogene (RET). The present disclosure also relates generally to methods of treating pancreatic cancer (e.g., an advanced pancreatic cancer, a metastatic pancreatic cancer, a pancreatic adenocarcinoma, a metastatic pancreatic adenocarcinoma, an MSI-H pancreatic cancer, a pancreatic ductal adenocarcinoma, a metastatic pancreatic ductal adenocarcinoma) in a human patient, comprising administering to the human patient (i) an anti-GFRAL antibody, wherein the antibody inhibits GFRAL binding to RET; (ii) paclitaxel; and (iii) gemcitabine.

Novel lactic acid bacterium L8 strain and a composition including the same L8 strain, the composition having blood glucose level reducing action, a lipid metabolism improving action, an antioxidant action, an antiobesity action, a fatty liver suppressing action, a hepatitis preventing action, a liver function improving action, and an intestinal environment improving action. A Lactococcus lactis subsp. lactis L8 strain derived from Amur cork living in the Shirakami Mountains, a composition containing the strain, and a medium and a method for efficiently culturing the strain.

An object of one present invention is to provide a food composition including, as an active ingredient thereof, Lactobacillus mucosae that has a function of improving a gut microbiota. An object of another present invention is to provide an increasing drug for the rate of bifidobacteria in the human intestine and a bifidobacteria proliferation promoting drug, including Lactobacillus mucosae as an active ingredient thereof. The one present invention provides a composition for improving the gut microbiota, including the bacterial cell or a culture of Lactobacillus mucosae as an active ingredient thereof. The other present invention provides an increasing drug for the rate of bifidobacteria in the human intestine and a bifidobacteria proliferation promoting drug, including Lactobacillus mucosae as an active ingredient thereof.

An object of one present invention is to provide a food composition including, as an active ingredient thereof, Lactobacillus mucosae that has a function of improving a gut microbiota. An object of another present invention is to provide an increasing drug for the rate of bifidobacteria in the human intestine and a bifidobacteria proliferation promoting drug, including Lactobacillus mucosae as an active ingredient thereof. The one present invention provides a composition for improving the gut microbiota, including the bacterial cell or a culture of Lactobacillus mucosae as an active ingredient thereof. The other present invention provides an increasing drug for the rate of bifidobacteria in the human intestine and a bifidobacteria proliferation promoting drug, including Lactobacillus mucosae as an active ingredient thereof.